NetworkNewsBreaks – Soleno Therapeutics, Inc. (NASDAQ: SLNO) Obtains New US Patent for DCCR to Treat PWS, SMS

Shares of Soleno Therapeutics (NASDAQ: SLNO) are up 5% following the company’s news this morning that it has received a newly-issued patent (9,757,384) from the U.S. Patent and Trademark Office protecting the use of pharmaceutical formulations of diazoxide and its salts, including the company’s diazoxide choline controlled-release tablet (DCCR), to reduce one or more aggressive behaviors in a subject with Prader-Willi syndrome (PWS) or Smith-Magenis syndrome (SMS). The patent will provide protection to the company regarding associated claims into 2035. Soleno expects to commence a phase 3 clinical trial of DCCR in PWS by year-end 2017. “This patent will further strengthen the intellectual property portfolio for DCCR, our lead product candidate, for the treatment of PWS,” Soleno Therapeutics chief executive officer Anish Bhatnagar, M.D., stated in the news release.

To view the full press release, visit:

About Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc. is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company is currently advancing its lead candidate, DCCR, a once-daily oral tablet for the treatment of PWS, into a Phase III clinical development program at the end of 2017. Soleno, through its wholly-owned subsidiary, Capnia, Inc., continues to market Capnia’s innovative medical device, the CoSense® End-Tidal Carbon Monoxide (ETCO) monitor, which measures ETCO and is used by hospitals to detect hemolysis in newborns.  It is expected that this product will be monetized and will not be a focus for the company in the long term. For more information, please visit

More from NetworkNewsBreaks

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information please visit

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s